Kopran (BOM:524280) Cyclically Adjusted Revenue per Share: ₹129.02 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524280 Kopran Ltd BOM:524280
68 GF Score
Price ₹203.90
GF Value ₹215.82
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Kopran Cyclically Adjusted Revenue per Share?

Kopran BOM:524280 +1.65% 68 Cyclically Adjusted Revenue per Share is ₹129.02 as of Jun. 2026. GuruFocus rates BOM:524280 with a GF Score™ of 68/100 and a GF Value™ of ₹215.82 (Fairly Valued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Kopran's adjusted revenue per share for the three months ended in Jun. 2026 was ₹31.944. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹129.02 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Kopran's average Cyclically Adjusted Revenue Growth Rate was 7.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 4.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Kopran was 4.80% per year. The lowest was 4.80% per year. And the median was 4.80% per year.

As of today (2026-08-20), Kopran's current stock price is ₹203.90. Kopran's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹129.02. Kopran's Cyclically Adjusted PS Ratio of today is 1.58.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Kopran was 3.22. The lowest was 0.92. And the median was 1.72.


Kopran  (BOM:524280) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Kopran's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=203.90/129.02
=1.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Kopran was 3.22. The lowest was 0.92. And the median was 1.72.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Kopran Cyclically Adjusted Revenue per Share Related Terms


Kopran Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Kopran's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kopran Cyclically Adjusted Revenue per Share Chart

Kopran Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 102.29 109.33 114.69 117.88 125.76

Kopran Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 120.03 121.27 123.10 125.76 129.02

BOM:524280 vs LLY, JNJ, ABBV: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Kopran's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kopran Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kopran's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Kopran's Cyclically Adjusted PS Ratio falls into.


BOM:524280
68GF Score
Kopran Ltd BOM:524280
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kopran Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Kopran's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=31.944/167.3573*167.3573
=31.944

Current CPI (Jun. 2026) = 167.3573.

Kopran Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 18.141 105.961 28.652
201612 18.376 105.196 29.235
201703 22.369 105.196 35.587
201706 11.858 107.109 18.528
201709 16.916 109.021 25.968
201712 21.850 109.404 33.424
201803 22.257 109.786 33.928
201806 13.820 111.317 20.777
201809 21.233 115.142 30.862
201812 24.373 115.142 35.426
201903 20.916 118.202 29.614
201906 18.936 120.880 26.217
201909 20.264 123.175 27.533
201912 23.168 126.235 30.715
202003 18.069 124.705 24.249
202006 27.946 127.000 36.826
202009 27.476 130.118 35.340
202012 25.892 130.889 33.106
202103 29.917 131.771 37.997
202106 17.420 134.084 21.743
202109 29.483 135.847 36.322
202112 30.469 138.161 36.908
202203 28.953 138.822 34.904
202206 26.131 142.347 30.722
202209 24.383 144.661 28.209
202212 32.756 145.763 37.609
202303 30.645 146.865 34.921
202306 24.472 150.280 27.253
202309 31.583 151.492 34.891
202312 32.904 152.924 36.009
202403 37.616 153.035 41.137
202406 28.904 155.789 31.050
202409 31.404 157.882 33.289
202412 34.384 158.323 36.346
202503 35.622 157.552 37.839
202506 27.953 159.755 29.283
202509 24.477 162.289 25.241
202512 40.147 163.281 41.149
202603 48.502 164.272 49.413
202606 31.944 167.357 31.944

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹129.02 mean?
Kopran (BOM:524280) has a Cyclically Adjusted Revenue per Share of ₹129.02 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Kopran and its competitors.
Is Kopran's Cyclically Adjusted Revenue per Share too high?
Kopran's current Cyclically Adjusted Revenue per Share is ₹129.02. Overall, Kopran has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kopran's Cyclically Adjusted Revenue per Share compare to LLY and JNJ?
Kopran's Cyclically Adjusted Revenue per Share of ₹129.02 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Kopran and its competitors. Kopran's current Cyclically Adjusted Revenue per Share is ₹129.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kopran stock overvalued right now?
Based on GuruFocus' analysis, Kopran (BOM:524280) is currently considered Fairly Valued. The stock's GF Value™ is ₹215.82, compared to a current price of ₹203.90 — trading 5.5% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹129.02. Kopran's overall GF Score™ is 68/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Kopran (BOM:524280), the current Cyclically Adjusted Revenue per Share is ₹129.02 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kopran (BOM:524280) Overvalued in 2026?

Based on GuruFocus' analysis, Kopran stock appears to be undervalued. The current stock price of ₹203.90 is trading 5.5% below its estimated GF Value™ of ₹215.82. GuruFocus considers Kopran to be Fairly Valued.

Key valuation signals for BOM:524280:

  • Cyclically Adjusted Revenue per Share: ₹129.02
  • GF Value™: ₹215.82 vs. price of ₹203.90 (5.5% below fair value)
  • GF Score™: 68/100 with 8 warning signs

No single metric tells the full story. See the BOM:524280 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kopran Business Description

Other Exchanges KOPRAN:India
Address Dr. E. Moses Road, 1076, Parijat House, Worli, Mumbai, MH, IND, 400 018
Kopran Ltd is an Indian based pharmaceutical company. It is engaged in manufacturing of Formulation (Finished Dosage Form) and Active Pharmaceutical Ingredients (API) i.e., Pharmaceuticals. It manufactures dosage forms including, tablets, capsules, dry powder, suspension, and injectables. Some of its product range includes antibiotics, cardiovascular, anti-diabetes, respiratory, pain management, and gastrointestinal. Geographically, it has a presence in India; South Africa; Ethiopia; Zambia; Egypt; Jordan and Rest of World.
68GF Score

Get the complete analysis for BOM:524280

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹203.90
Price
₹215.82
GF Value